Onco Actu du 18 novembre 2015

	3.1 Tabac
Smokeless Tobacco Users Had Higher Levels of Exposure to Nicotine and a Potent Carcinogen Than Cigarette Smokers [AACR] “Even though smokeless tobacco is used less than cigarettes, it continues to be used among several population groups, particularly men and young people, which is a cause for concern because it has been found to have several adverse health effects and identified as a cause of cancer.”
	4.1 Dép., diag. & prono. - Prostate
Prostate Screening Drops Sharply, And So Do Cancer Cases [NPR] "The take-home message to me is that the American public actually did listen to the U.S. Preventive Services Task Force."
Early Prostate Cancer Cases Fall Along With Screening [NY Times] The declines “could have significant public health implications,” one study said, and almost certainly result from a panel’s recommendation against the hotly debated test.
Prostate cancer screening, early cases, in decline [Reuters] "I’m hoping that men are being allowed to make a choice and this decline reflects the fact that they prefer not to be screened," said study author Dr. Otis Brawley, who is chief medical officer for the American Cancer Society in Atlanta.
	4.12 Biopsies liquides
Big Bucks, Tiny Bubbles: Ex-Biogen Exec’s Exosome Startup Nabs $80M [Xconomy] Williams says Codiak will first try to make exosome-based drugs and diagnostics for pancreatic cancer, and should be in the clinic testing its first candidate next year.
ARCH Venture Partners, Flagship Ventures and MD Anderson collaborate to launch Codiak BioSciences [MD Anderson Cancer Center] Company secures $80-plus million in committed funding to develop exosome-based therapeutic and diagnostic products.
Companies seek to diagnose cancer using exosomes [STAT] The company, which was primarily funded by Arch Venture Partners and Flagship Ventures, is cofounded by Eric Lander, the founding director of the Broad Institute, and will be led by Douglas Williams, most recently the executive vice president of research and development at Biogen.
	5. Traitements
Investigational Immunotherapeutic Increased Bladder Cancer Survival [AACR] In this study, we assessed whether a novel immunotherapeutic approach that we have devised, called personalized peptide vaccination, could improve outcomes for patients who have advanced bladder cancer that has progressed after platinum-based chemotherapy.
Pancreatic cancer treatment 'breakthrough' - Ulster University [BBC News] "This really is a groundbreaking development and one of the most promising advances in pancreatic cancer research for decades." "We are hopeful that within the next one to two years we can start to begin clinical trials with this technology."
	5.2.1 Pharma - Partenariats
AstraZeneca teams with tiny Cerulean on an NCI cancer combo study [FierceBiotech] Cerulean's CRLX101 uses a nano delivery vehicle to dispatch small doses of the highly toxic camptothecin directly to targeted cancer cells. But in a Phase IIb drug study back in 2013, the drug flopped badly.
	5.2.3 Pharma - économie
Can Pharma Clean Up Its Act on Drug Pricing? Q&A With Alnylam CEO John Maraganore [Forbes] "I think the value part of it is important. It’s not about the prices are of drugs, it’s about the value that it ultimately delivers."
European biotech gets boost as Genmab market value hits $7 billion [Reuters] Genmab has struck deals to give away rights to partners in exchange for them funding development. The approach made sense for a drug like Darzalex, which Genmab could never have afforded to develop on its own, while J&J has devoted hundreds of staff to getting the medicine to market.
	5.3 Traitements - FDA, EMA,...
Robert Califf, F.D.A. Nominee, Queried on Industry Ties [NY Times] Senators questioned Dr. Califf, a cardiologist whose consulting work for the pharmaceutical industry has raised questions among some public health groups.
	5.4 Traitements - Economie
Roche breast cancer drug rejected by agency again over price [STAT] The decision means that the UK’s National Health Service will not cover the $137,000 per patient cost of the drug for women in Scotland and Wales. However, Roche struck a separate deal so that a special government fund will foot the bill for women in England.
NICE: Kadcyla price still too high [NICE] Although retained for use through the Cancer Drugs Fund, Roche’s breast cancer combination treatment, Kadcyla (trastuzumab emtansine), will not be recommended for routine NHS use because its price remains too high.
AstraZeneca's Tagrisso to cost $12,750 for a month's supply [Reuters] AstraZeneca has previously said it believes Tagrisso could generate peak sales of $3 billion a year, making it a key product in the group's growing oncology portfolio.
	5.7.1 SABCS-communiqués
Myriad Will Present Eight Studies at the 2015 San Antonio Breast Cancer Symposium [Myriad] New Data on the myChoice® HRD and myRisk™ Hereditary Cancer Tests Will be Highlighted.
NewLink Genetics Corporation Announces Phase 2 Data on Indoximod at the San Antonio Breast Cancer Symposium [NewLink Genetics] A phase 2 randomized trial of the IDO pathway inhibitor indoximod in combination with taxane based chemotherapy for metastatic breast cancer: preliminary data.
	6. Lutte contre les cancers
Rebuilding Trust In Medicine: How The Public Can Interpret Differing Guidelines [Health Affairs Blog] Just 23 percent of people in the U.S. have “great confidence” in doctors (down from 73 percent in 1966). Why? The NEJM authors believe that some of the frustration may relate to the very public disagreements between “experts”—specialty societies, expert panels convened by the government, and researchers who build and report the evidence—on what should be done, for whom, and when, in routine clinical practice.
	6.10 Politiques
Most voters want presidential candidates to hold down drug prices, survey says [STAT] If you thought prescription drug prices would not remain a key issue in the presidential campaign, think again.
ASCO Calls on Congress to Reinvest in Cancer Research [ASCO] “As our population ages, cancer is expected to become the leading cause of death in the U.S. by 2030. We cannot afford for promising research to continue to go unfunded, for new studies to be scaled back, and for fewer cancer patients have access to clinical trials. It is time for Congress to right this wrong by seizing this opportunity to provide increased funding for NIH and NCI."
	6.5 Médecines alternatives
“The Truth About Cancer” Series Is Untruthful About Cancer [Science-Based Medicine] I predict that Bollinger will have blood on his hands: people will die because they believed this was “the truth about cancer” and were persuaded to reject lifesaving treatment.
Will Stanislaw Burzynski finally face real justice? [Respectful Insolence] Over just that five years, I became quite disheartened at Burzynski’s seemingly undefeatable ability to evade justice and keep doing what he’s doing, FDA and TMB be damned. This time around, I feel an optimism that I haven’t felt in a long time about the prospects of finally shutting Burzynski down and preventing him from preying on desperate cancer patients any more.